News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Burzynski Research Institute Receives Orphan Drug Designation For Antineoplastons A10 And AS2-1 For Treatment Of Brain Stem Glioma



10/19/2005 5:10:19 PM

Burzynski Research Institute (BRI) (OTCBB:BZYR) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for its drug candidates Antineoplastons A10 and AS2-1 for the treatment of brain stem glioma.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES